655 related articles for article (PubMed ID: 25092589)
1. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Society of Urological Pathology, Association of Directors of Anatomic and Surgical Pathology, the New Zealand Society of Pathologists, and the Prostate Cancer Foundation.
Amin MB; Lin DW; Gore JL; Srigley JR; Samaratunga H; Egevad L; Rubin M; Nacey J; Carter HB; Klotz L; Sandler H; Zietman AL; Holden S; Montironi R; Humphrey PA; Evans AJ; Epstein JI; Delahunt B; McKenney JK; Berney D; Wheeler TM; Chinnaiyan AM; True L; Knudsen B; Hammond ME
Arch Pathol Lab Med; 2014 Oct; 138(10):1387-405. PubMed ID: 25092589
[TBL] [Abstract][Full Text] [Related]
2. Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist.
Montironi R; Hammond EH; Lin DW; Gore JL; Srigley JR; Samaratunga H; Egevad L; Rubin MA; Nacey J; Klotz L; Sandler H; Zietman AL; Holden S; Humphrey PA; Evans AJ; Delahunt B; McKenney JK; Berney D; Wheeler TM; Chinnaiyan A; True L; Knudsen B; Epstein JI; Amin MB; ; ;
Virchows Arch; 2014 Dec; 465(6):623-8. PubMed ID: 25316188
[TBL] [Abstract][Full Text] [Related]
3. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
[TBL] [Abstract][Full Text] [Related]
4. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
5. Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance.
Mazzucchelli R; Galosi AB; Lopez-Beltran A; Scarpelli M; Cheng L; Montironi R
Arch Ital Urol Androl; 2014 Dec; 86(4):314-8. PubMed ID: 25641461
[TBL] [Abstract][Full Text] [Related]
6. NIH State-of-the-Science Conference Statement: Role of active surveillance in the management of men with localized prostate cancer.
Ganz PA; Barry JM; Burke W; Col NF; Corso PS; Dodson E; Hammond ME; Kogan BA; Lynch CF; Newcomer L; Seifter EJ; Tooze JA; Viswanath KV; Wessells H
NIH Consens State Sci Statements; 2011 Dec 5-7; 28(1):1-27. PubMed ID: 23392076
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance as a therapeutic option for patients with low-risk prostate cancer according to the 2014 International Society of Urological Pathology grading system: a review.
Helpap B; Gevensleben H
Scand J Urol; 2017 Feb; 51(1):1-4. PubMed ID: 27967297
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens.
Amin M; Boccon-Gibod L; Egevad L; Epstein JI; Humphrey PA; Mikuz G; Newling D; Nilsson S; Sakr W; Srigley JR; Wheeler TM; Montironi R
Scand J Urol Nephrol Suppl; 2005 May; (216):20-33. PubMed ID: 16019757
[TBL] [Abstract][Full Text] [Related]
9. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
Chen RC; Rumble RB; Loblaw DA; Finelli A; Ehdaie B; Cooperberg MR; Morgan SC; Tyldesley S; Haluschak JJ; Tan W; Justman S; Jain S
J Clin Oncol; 2016 Jun; 34(18):2182-90. PubMed ID: 26884580
[TBL] [Abstract][Full Text] [Related]
10. Aligning evidence and practice: future research needs to increase utilization of active surveillance for favorable risk prostate cancer.
Carter HB
Curr Opin Urol; 2015 May; 25(3):277-82. PubMed ID: 25692722
[TBL] [Abstract][Full Text] [Related]
11. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance in men with localized prostate cancer: a systematic review.
Dahabreh IJ; Chung M; Balk EM; Yu WW; Mathew P; Lau J; Ip S
Ann Intern Med; 2012 Apr; 156(8):582-90. PubMed ID: 22351515
[TBL] [Abstract][Full Text] [Related]
13. Update on the Gleason grading system for prostate cancer: results of an international consensus conference of urologic pathologists.
Epstein JI; Allsbrook WC; Amin MB; Egevad LL
Adv Anat Pathol; 2006 Jan; 13(1):57-9. PubMed ID: 16462155
[TBL] [Abstract][Full Text] [Related]
14. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study.
Ström P; Kartasalo K; Olsson H; Solorzano L; Delahunt B; Berney DM; Bostwick DG; Evans AJ; Grignon DJ; Humphrey PA; Iczkowski KA; Kench JG; Kristiansen G; van der Kwast TH; Leite KRM; McKenney JK; Oxley J; Pan CC; Samaratunga H; Srigley JR; Takahashi H; Tsuzuki T; Varma M; Zhou M; Lindberg J; Lindskog C; Ruusuvuori P; Wählby C; Grönberg H; Rantalainen M; Egevad L; Eklund M
Lancet Oncol; 2020 Feb; 21(2):222-232. PubMed ID: 31926806
[TBL] [Abstract][Full Text] [Related]
15. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer.
Womble PR; Montie JE; Ye Z; Linsell SM; Lane BR; Miller DC;
Eur Urol; 2015 Jan; 67(1):44-50. PubMed ID: 25159890
[TBL] [Abstract][Full Text] [Related]
16. Active surveillance of prostate cancer: a questionnaire survey of urologists, clinical oncologists and urology nurse specialists across three cancer networks in the United Kingdom.
Philippou Y; Raja H; Gnanapragasam VJ
BMC Urol; 2015 Jun; 15():52. PubMed ID: 26070313
[TBL] [Abstract][Full Text] [Related]
17. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
18. Essential Updates in Grading, Morphotyping, Reporting, and Staging of Prostate Carcinoma for General Surgical Pathologists.
Paner GP; Gandhi J; Choy B; Amin MB
Arch Pathol Lab Med; 2019 May; 143(5):550-564. PubMed ID: 30865487
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance guidance for New Zealand men with low-risk prostate cancer.
Nacey J; Delahunt B; Mark S; Matthews J; Williams A; White T; Simpson A
N Z Med J; 2015 Aug; 128(1420):13-5. PubMed ID: 26367508
[No Abstract] [Full Text] [Related]
20. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
